课题基金 / 基金详情

项目摘要

项目成果

Wenqing Xu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Protein poly (ADP-ribosyl) ation (PARylation) is an important posttranslational modification that regulates cell-survival and cell-death programs, and is being recognized as playing a role in an increasing number of other biological functions. Recent observations suggest that, in some cases, PARylation of a protein serves as a signal for its ubiquitination and degradation. Axin is the first example in which the PARylation-dependent ubiquitination and degradation has been clearly demonstrated. Our collaborators have recently identified RNF146 as a key protein for ubiquitinating PARylated Axin. RNF146 contains only two conserved domains, a RING domain that is likely an E3 ubiquitin ligase, and a WWE domain with unknown function. Now our biochemical analyses demonstrate that the RNF146 WWE domain is a specific poly (ADP- ribose) (PAR) binding domain. Strikingly, most WWE-domain containing proteins also contain an E3 ubiquitin ligase domain (either a RING or a HECT domain). This suggests that there may be a family of E3 ubiquitin ligases that use their WWE domains to specifically recognize PARylated proteins as their ubiquitination substrates. In this proposal, we have two major goals. The first is to further characterize the specific RNF146 WWE-PAR interaction, to reveal the structural basis of this recognition through structural determination, and to analyze the molecular mechanism underlying PARylation-dependent ubiquitination by RNF146. These studies will provide a paradigm for understanding protein PARylation and PARylation-dependent ubiquitination. The second goal is to determine crystal structures of poly (ADP-ribose) glycohydrolase (PARG), the only known enzyme responsible for PAR degradation in the cell and a drug target for cancer and other diseases, and its complexes with the PARG substrate and inhibitors. This line of research will be critical not only for understanding the molecular mechanism of PARG catalysis, regulation, but also for developing better PARG inhibitors. The availability of specific PARG inhibitors will have a significant impact on efforts to explore the biological role of protein PARylation in addition to their potential therapeutic value.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An inducible protein knockout strategy based on an orthogonal, ligand-activated E3 ubiquitin ligase
  • 批准号:
    9112804
  • 项目类别:
  • 资助金额:
    $23.15万
  • 财政年份:
    2016
  • 负责人:
    Wenqing Xu
  • 依托单位:
Structural Analysis of Cancerous Inhibitor of PP2A (CIP2A)
  • 批准号:
    9282805
  • 项目类别:
  • 资助金额:
    $16.8万
  • 财政年份:
    2016
  • 负责人:
    Wenqing Xu
  • 依托单位:
Structural Basis of Norrin-induced Wnt/beta-catenin signaling
  • 批准号:
    9006448
  • 项目类别:
  • 资助金额:
    $38.63万
  • 财政年份:
    2016
  • 负责人:
    Wenqing Xu
  • 依托单位:
Structural and biochemical studies of protein PARylation and PARylation-dependent
  • 批准号:
    8644805
  • 项目类别:
  • 资助金额:
    $28.4万
  • 财政年份:
    2012
  • 负责人:
    Wenqing Xu
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: